Citadel Advisors LLC Has $33,000 Holdings in Phio Pharmaceuticals Corp (NASDAQ:PHIO)

Citadel Advisors LLC lifted its stake in shares of Phio Pharmaceuticals Corp (NASDAQ:PHIO) by 148.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 85,621 shares of the company’s stock after buying an additional 51,216 shares during the period. Citadel Advisors LLC owned about 0.36% of Phio Pharmaceuticals worth $33,000 as of its most recent SEC filing.

Separately, SG Americas Securities LLC increased its holdings in shares of Phio Pharmaceuticals by 163.8% during the second quarter. SG Americas Securities LLC now owns 603,528 shares of the company’s stock worth $229,000 after buying an additional 374,703 shares in the last quarter. Hedge funds and other institutional investors own 5.27% of the company’s stock.

Separately, ValuEngine upgraded shares of Phio Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd.

NASDAQ PHIO opened at $0.21 on Friday. The company has a market capitalization of $5.76 million, a price-to-earnings ratio of -0.20 and a beta of 1.67. Phio Pharmaceuticals Corp has a twelve month low of $0.20 and a twelve month high of $0.53. The stock has a fifty day simple moving average of $0.30 and a 200 day simple moving average of $0.39. The company has a quick ratio of 5.87, a current ratio of 5.87 and a debt-to-equity ratio of 0.05.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.08) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.08). Research analysts expect that Phio Pharmaceuticals Corp will post -0.36 earnings per share for the current fiscal year.

Phio Pharmaceuticals Profile

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Recommended Story: Consumer Price Index (CPI)

Want to see what other hedge funds are holding PHIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phio Pharmaceuticals Corp (NASDAQ:PHIO).

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.